# Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

> **NCT06668753** · — · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 114 (estimated)

## Conditions studied

- Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab

## Key facts

- **NCT ID:** NCT06668753
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668753, "Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06668753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*